Although this study provides key insights into the pathogenic mechanism of NPM1-mutated AML and suggests the NPMc+/PDCD4 complex could be a potential therapeutic target for this subtype of AML, several limitations should be acknowledged. The gene discussed is NPM1; the disease is acute myeloid leukemia.